Poster

Development of a human PBMC TXG-MAPr as a mechanistic framework to interpret toxicodynamic variability across the human population

Leiden University and EFSA researchers present the PBMC TXG-MAPr — a network-based transcriptomic tool mapping…

CertaraJune 23, 2026

Poster

Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteers

Research from Leiden University and EFSA characterizing interindividual toxicodynamic variability using peripheral blood mononuclear cells…

CertaraJune 23, 2026

Announcement

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Integrated offering combines drug development, regulatory, commercial, and investor strategy expertise to help early-stage biotech…

Danielle PillsburyJune 23, 2026

Poster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

CertaraJune 23, 2026

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Poster

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Discover how Quantitative Systems Pharmacology (QSP) was used to predict cytokine release syndrome risk and…

CertaraJune 23, 2026

Poster

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Authors: Ibtissem Rebai (Certara), Stephen Duffull (Certara), Ayman Akil (Certara), Anna Largajolli (Certara), Floris Fauchet…

CertaraJune 22, 2026

Poster

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Discover how the AI/ML Special Interest Group is advancing responsible artificial intelligence in pharmacometrics through…

CertaraJune 22, 2026

Poster

Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization

Discover how active learning and Bayesian optimization improve virtual population generation for quantitative systems pharmacology…

CertaraJune 18, 2026

Poster

Mechanistic QSP Modeling to Support KIT Inhibitor Dose Selection, Biomarker Strategy, and Clinical Development

Discover how a mechanistic quantitative systems pharmacology (QSP) model predicts mast cell inhibition and depletion…

CertaraJune 16, 2026

Certara Services

Development of a human PBMC TXG-MAPr as a mechanistic framework to interpret toxicodynamic variability across the human population

Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteers

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization

Mechanistic QSP Modeling to Support KIT Inhibitor Dose Selection, Biomarker Strategy, and Clinical Development

Newsletter sign up

Quick links

Solutions

Contact